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ABSTRACT 59 
To discover novel genes underlying amyotrophic lateral sclerosis (ALS), we aggregated exomes 60 
from 3,864 cases and 7,839 ancestry matched controls. We observed a significant excess of rare 61 
protein-truncating variants among ALS cases, which was concentrated in constrained genes. 62 
Through gene level analyses, we replicated known ALS genes including SOD1, NEK1, and FUS. 63 
We also observed multiple distinct protein-truncating variants in a highly constrained gene, 64 
DNAJC7. The signal in DNAJC7 exceeded genome-wide significance and immunoblotting 65 
assays showed depletion of DNAJC7 protein in fibroblasts in an ALS patient carrying the 66 
p.Arg156Ter variant. DNAJC7 encodes a member of the heat shock protein family (HSP40), 67 
which along with HSP70 proteins, facilitate protein homeostasis including folding of newly 68 
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synthesized polypeptides and clearance of degraded proteins. When these processes are not 69 
regulated, misfolding and accumulation of aberrant proteins can occur leading to protein 70 
aggregation, a pathological hallmark of neurodegeneration. Our results highlight DNAJC7 as a 71 
novel gene for ALS. 72 
 73 
KEYWORDS 74 
Amyotrophic lateral sclerosis; protein truncating variants; neurodegeneration; rare variants; 75 
DNAJC7. 76 
 77 
INTRODUCTION 78 
Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease characterized 79 
primarily by degeneration of motor neurons leading to progressive weakness of limb, bulbar, and 80 
respiratory muscles1,2. Genetic variation is an important risk factor for ALS. Given that 5-10% of 81 
patients report a positive family history2 and ~10% of sporadic patients carry known familial 82 
ALS gene mutations, the distinction between familial and sporadic disease is increasingly 83 
blurred3. Until recently, ALS gene discoveries were made through large multigenerational 84 
pedigrees in which the gene and the causal variant segregated in an autosomal dominant 85 
inheritance pattern with very few cases of autosomal recessive inheritance reported. Collecting 86 
sporadic case samples has been valuable for gene discovery in more common disorders such as 87 
schizophrenia4, inflammatory bowel disease5, and type 2 diabetes6, and can have profound 88 
effects on the success of targeted therapeutic approaches2,7,8. The most recent ALS genetic 89 
discoveries using large massively parallel sequencing data yielded several gene discoveries 90 
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including TBK1, TUBA4A, ANXA11 and NEK1 and KIF5A9-13; in addition to other risk loci in 91 
C21orf2, MOBP, and SCFD114. 92 
Herein, we have assembled the largest ALS exome case-control study to date, consisting 93 
of 11,703 individuals (3,864 cases and 7,839 controls). We complemented our analysis by 94 
leveraging allele frequencies from large external exome sequencing databases in DiscovEHR 95 
(>50,000 samples) and a subset of ExAC (>45,000 samples). In our analysis, we observed an 96 
excess of rare protein truncating variants in ALS cases, which primarily resided in genes under 97 
strong purifying selection and therefore, are less likely to tolerate deleterious mutations 98 
(constrained genes). Furthermore, through gene burden testing in which multiple independent 99 
variants are harbored in the same gene therefore, implicating that gene in a disease, we 100 
confirmed the known association of SOD1, NEK1, and FUS in ALS. Interestingly, we observed 101 
multiple, distinct protein-truncating variants in DNAJC7 in our cohort and in an independent, 102 
replication cohort. In our analysis, the signal in DNAJC7 exceeded genome-wide significance 103 
and immunoblotting showed depletion of DNAJC7 in fibroblasts from an ALS patient carrying 104 
the p.Arg156Ter protein truncating variant. DNAJC7 is a highly constrained gene, and encodes a 105 
DNAJ molecular chaperone, which facilitates protein maintenance and quality control, such as 106 
folding of newly synthesized polypeptides, and clearance of degraded proteins15. Dysregulation 107 
of these processes can lead to aberrant protein aggregation, one of the pathological hallmarks of 108 
neurodegenerative diseases. 109 
 110 
RESULTS 111 
Patient demographics and dataset overview 112 
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We processed our initial dataset of 15,722 samples through a rigorous quality control pipeline 113 
using Hail, an open-source, scalable framework for exploring and analyzing genomic data 114 
https://hail.is/. All samples were screened for the C9orf72 hexanucleotide expansion (G4C2) and 115 
positive samples were excluded from our study. We removed samples with poor sequencing 116 
quality, high levels of sequence contamination, closely related with one another, ambiguous sex 117 
status, or population outliers per PCA (Supplementary Table 1; Supplementary Fig. 1-2). Our 118 
final data set consisted of 3,864 cases and 7,839 controls for a total of 11,703 samples. 119 
Individuals were of European descent with 7,355 (62.8%) and 4,348 (37.2%) of samples 120 
classified as males and females, respectively. Of 3,864 cases, 2,274 (58.9%) and 1,590 (41.1%) 121 
samples were classified as males and females, respectively; where 5,081 (64.8%) and 2,758 122 
(35.2%) were classified as males in controls. 123 
 124 
Excess of exome-wide rare protein truncating variants 125 
We assessed four models that incorporated different covariates and assessed their stringency and 126 
performance by controlling for benign or synonymous variation. Specifically, each model uses 127 
firth based logistic regression and incorporates some or all the covariates: 1) sample sex, 2) PC1-128 
PC10, and either 3) the total exome count (summation of synonymous variants, benign missense 129 
variants, damaging missense variants, and protein-truncating variants) or 4) benign variation 130 
(summation of synonymous and benign missense variants). We show the results from the most 131 
conservative model (model 3), which used all the covariates and the total exome count. Under 132 
these models, we evaluated four classes of allele frequency thresholds: (1) singletons, which are 133 
variants present in a single individual in our dataset (allele count, AC =1); (2) doubletons, which 134 
are present in two individuals in our dataset (AC = 2); (3) ultra-rare singletons, which are 135 
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singletons in our dataset and are absent in DiscovEHR, a large, independent exome dataset (AC 136 
= 1, 0 in DiscovEHR); and finally, (4) rare variants, which have an allele frequency of of <0.01% 137 
in our dataset (11,703 samples), in ExAC (non-psychiatric studies, >45,000 samples) and in 138 
DiscovEHR (>50,000 samples). For a full explanation of these models and allele frequency 139 
thresholds, please see the Methods section. 140 
Using model 3, we observed a significant enrichment of singleton protein-truncating 141 
variants in ALS cases relative to controls (OR: 1.07, P: 5.00×10-7); ultra-rare singleton PTVs 142 
(OR: 1.08, P: 1.97×10-6); and rare PTVs (OR: 1.04, P: 1.77×10-7) (Fig. 1). These values all 143 
passed multiple test correction (P<0.0125). The number of doubletons (AC=2) was too low to 144 
detect any significant enrichment. 145 
When using model 4 ZKHUHZHUHVWULFWWRµEHQLJQYDULDWLRQ¶DVWKHILQDOFRYDULDWH the 146 
protein-truncating variants signal is further enriched among singletons (OR: 1.12, P: <2×10-16); 147 
ultra-rare singletons (OR: 1.10, P: 1.53×10-10); and rare variants (OR: 1.04, P: 1.47×10-7). 148 
Interestingly, in this analysis, there is a consistent and a significant enrichment of damaging 149 
missense variants not observed in the previous analysis: singletons (OR: 1.06, P: <2×10-16); 150 
ultra-rare singletons (OR: 1.03, P: 6.33×10-5); and rare variants (OR: 1.01, P: 3.24×10-3). 151 
In our analyses, we use a standard definition of protein-truncating variants as frameshift 152 
variants, splice acceptor variants, splice donor variants, or stop gained variants, which are due to 153 
insertions or deletions (indels), or single nucleotide variants (SNVs). Given the known elevated 154 
error rate in indels we divided all protein-truncating variants as either SNVs or indels and 155 
repeated the exome-wide analysis to eliminate any false positive signals. The significant signal is 156 
present in both SNVs and indels: SNV singletons (OR: 1.05, P: 2.99×10-3); indel singletons 157 
(OR: 1.10, P: 5.75×10-6); SNV ultra-rare singletons (OR: 1.06, P: 4.34×10-3); indel ultra-rare 158 
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singletons (OR: 1.12, P: 1.96×10-5); and SNV rare variants (OR: 1.03, P: 6.48×10-4); indel rare 159 
variants (OR: 1.05, P: 3.30×10-5) (Supplementary Fig. 4). This additional quality control test 160 
ensures that the protein-truncating variants signal is driven by both indels and SNVs and is 161 
unlikely to be false. 162 
 163 
Gene set testing: enrichment of rare variants in constrained genes 164 
To determine whether we could identify the source of the protein-truncating variants enrichment, 165 
we assessed multiple different gene sets. We evaluated: (1) constrained genes, which are a set of 166 
genes under strong purifying selection; (2) genes known to confer risk to ALS; (3) genes 167 
associated with clinically overlapping diseases such as other motor neuron diseases (primary 168 
lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and spinal muscular 169 
atrophy) as well as genes associated witKIURQWRWHPSRUDOGHPHQWLD3DUNLQVRQ¶VGLVHDVH3LFN¶V170 
GLVHDVHDQG$O]KHLPHU¶VGLVHDVH; and finally, (4) genes in which their expression is specific to 171 
the brain. 172 
Among constrained genes we observed a significant enrichment of singleton protein-173 
truncating variants (OR: 1.23, P: 7.74×10-7); ultra-rare singletons (OR: 1.27, P: 5.76×10-8), and 174 
rare variants (OR: 1.33, P: <2×10-16) (Fig. 2A, Supplementary Fig. 5A). We obtained similar 175 
results using model 4 (Supplementary Fig. 5A). To determine whether the entire signal can be 176 
explained by constrained genes, we removed them genes and reconducted the analysis. The 177 
significant enrichment signal persists however, the effect sizes are attenuated: singleton protein-178 
truncating variants (OR: 1.05, P: 3.30×10-4); ultra-rare singleton protein-truncating variants 179 
(OR: 1.05, P: 1.96×10-3); and rare protein-truncating variants (OR: 1.02, P: 2.93×10-3) (Fig. 2B, 180 
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Supplementary Fig. 5B). This enrichment was also observed in model 4 (Supplementary Fig. 181 
5B). 182 
Next, we evaluated the potential effects of known ALS genes. We did not include the 183 
ALS genes TBK1, NEK1, KIF5A, C21orf2, MOBP, or SCFD1 as these genes were discovered 184 
using datasets that contained a large subset of the same samples and can generate an amplified 185 
signal. The known ALS genes had negligible, insignificant effects (Fig. 3A, Supplementary Fig. 186 
6). When including variants from TBK1, NEK1, KIF5A, C21orf2, MOBP, or SCFD1, the 187 
negligible signals persist therefore, the initial observation of the exome-wide protein-truncating 188 
variant enrichment is not driven by known effects of ALS genes and is likely due to other 189 
genomic loci. 190 
Although ALS is traditionally considered to be a disease of upper and lower motor 191 
neurons, more than 50% of ALS patients exhibit neuropsychological and cognitive deficits, with 192 
up to 30% of ALS patients meeting some diagnostic criteria for frontotemporal dementia, and 193 
some patients may also exhibit Parkinsonism or Parkinsonism-dementia1,16-20. We tabulated a list 194 
of genes associated with other motor neuron diseases such as primary lateral sclerosis, 195 
progressive muscular atrophy, progressive bulbar palsy, and spinal muscular atrophy. We also 196 
included genes associated with IURQWRWHPSRUDOGHPHQWLD3DUNLQVRQ¶VGLVHDVH3LFN¶VGLVHDVHDQG197 
$O]KHLPHU¶VGLVHDVH (Supplementary Table 5). We did not observe a significant enrichment of 198 
variants in any class of variation, suggesting that the initial observation of protein-truncating 199 
variant enrichment is unlikely to be explained by only these genes (Fig. 3B, Supplementary Fig. 200 
7). 201 
Finally, we tested whether there is a signal in brain specific genes as ALS is a 202 
neurodegenerative disease with the predominant symptoms affecting the central nervous system. 203 
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We extracted a list of genes with specific brain expression generated using GTEx and performed 204 
the same burden analysis across classes of variation. We did not observe any significant 205 
differences in protein-truncating variants or damaging missense variation in any allele frequency 206 
threshold (Fig. 3C, Supplementary Fig. 8). 207 
 208 
Single gene burden analysis replicates previous ALS associations 209 
To determine whether a single gene is enriched for variation in ALS cases (ALS-associated) or 210 
depleted in ALS cases (ALS-protective), we evaluated ultra-rare (AC=1, absent in DiscovEHR) 211 
and rare (MAF <0.001% in our dataset, DiscovEHR, and ExAC) protein-truncating variants and 212 
damaging missense variants. Within the ultra-rare variant category, no individual gene passed 213 
exome-wide significance. However, the top genes were known ALS genes: (1) NEK1 (PTVs, 214 
OR: 12.21, P: 7.32×10-5); (2) OPTN (PTVs, OR: 20.33, P: 1.2×10-4); and (3) SOD1 (dmis, OR: 215 
46.91, P: 5.03×10-6) (Supplementary Fig. 9). Within rare protein-truncating variants, only NEK1 216 
(OR: 12.8, P: 4.59×10-9), passed exome-wide significance; the next top 9 most significant genes, 217 
which include FUS, a known ALS gene (OR: 26.4, P: 1.29×10-3), are displayed in Table 1, Fig. 218 
4A. Similarly, within damaging missense variants, SOD1 (OR: 87.7, P: 7.5×10-11) was the only 219 
gene to pass exome-wide significance; the top 9 most significant genes are displayed in Table 1, 220 
Fig. 4B. In Supplementary Tables 2 and 3, we tabulate the results of the single gene burden 221 
analysis for the proposed ALS genes based on the literature, as well as their odds ratio and P-222 
values. 223 
 To determine if we can reproduce the initial signals observed, we included an additional 224 
21,071 controls from ExAC that are of European descent (non-Finnish) and were not a part of 225 
any psychiatric or brain related studies, to eliminate any sample overlap. We performed the same 226 
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burden analyses using 3,864 cases and 28,910 controls (7,839 controls within our dataset and 227 
21,071 additional controls). In Tables 1 and 2, we display the most significant genes that were 228 
identified in the initial discovery and tabulate their OR and P-values for both the initial discovery 229 
cohort (3,864 cases and 7,839 controls) and the secondary analysis (3,864 cases and 28,910 230 
controls). Within protein-truncating variants, NEK1 is still the only gene that exceeds exome-231 
wide significance (OR: 6.5, P: 3.03×10-10) (Fig. 4C). Of the next 9 most significant genes in the 232 
initial analysis, the only signal that was strengthened was in FUS (OR: 97.4, P: 2.68×10-6). This 233 
finding suggests that the other genes may not be true positives or will need further evidence to 234 
support their association with ALS.  Interestingly, the signal in OPTN, a proposed ALS 235 
associated gene, decreased (OR: 6.6, P: 3.0×10-3 to OR: 2.6, P: 6.9×10-3) however, this may be 236 
explained in part by the observation that OPTN protein-truncating variants tend to manifest as a 237 
recessive form of ALS, which may not be detected in our burden model. With the additional 238 
controls, multiple genes had similar ORs as the discovery analysis, with their respective P-values 239 
approaching significance (P-values ranging from 7.7×10-5-1.4×10-3). Most notably, the signal 240 
in TBK1, a proposed ALS gene based on Cirulli et al. strengthened: (initial analysis; OR: 22.3, P: 241 
3.9×10-3; secondary analysis: OR: 12.5, P: 9.35×10-4). Within damaging missense variants, 242 
SOD1 is still the only gene that exceeds exome-wide significance (OR: 79.0, P: 6.0×10-18); 243 
however, the next 9 most significant genes no longer approach statistical significance. Similarly, 244 
when integrating additional controls, multiple genes approach significance (P-values ranging 245 
from 1.2×10-4-6.2×10-4) (Fig. 4D). 246 
 247 
Loss of function variants in DNAJC7 in ALS patients 248 
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DNAJC7, which is a highly constrained gene (pLI = 0.99) had 4 protein-truncating variants 249 
carriers in cases (3,864) and 0 in controls (7,839) in the discovery analysis (OR: 18.3, P: 0.01); 250 
and 0 protein-truncating variants in total controls (28,910) (OR: 96.1, P: 1.9×10-4). While 251 
DNAJC7 did not initially exceed genome-wide significance, its high constraint score and role in 252 
neurodegeneration as a member of the heat shock protein 40 (HSP40) family, encouraged us to 253 
evaluate additional datasets to determine its loss of function mutation frequency. 254 
 We surveyed data from the UK Motor Neurone Disease Association (n=1,135) and The 255 
Agnes Ginges Center for Human Neurogenetics at the Hadassah-Hebrew University Medical 256 
Center in Israel (n=96). We observed an additional 4 carriers for a total of 6 distinct protein-257 
truncating variants in 8 individuals with ALS (cases: 5,095; controls: 28,910; OR: 96.6, P: 258 
2.5×10-7) (Table 2). These DNAJC7 variants are extremely rare or completely absent from large 259 
population datasets such as gnomAD (Table 2). The DNAJC7 p.Phe163fs variant was observed 260 
in the Israeli cohort. As gnomAD does not currently provide variant frequency on individuals of 261 
Middle Eastern ethnicity, we screened an additional 3,244 controls from a mixture of Middle 262 
Eastern ethnicities for the p.Phe163fs variant and did not observe any carriers further 263 
demonstrating its rarity in the general population and an ancestry matched population. In 264 
addition, we also observed 15 rare missense variants in DNAJC7, of which 4 are predicted to 265 
exert a damaging effect in 5 ALS cases and 1 in control (Table 2). 266 
 We next proceeded to ask if any of the protein-truncating variants in DNAJC7 can affect 267 
its mRNA or protein levels. Accordingly, we collected total RNA from human fibroblasts 268 
derived from healthy controls and a patient with a DNAJC7 protein-truncating variant 269 
p.Arg156Ter and performed qRT-PCR with two different sets of primer pairs to investigate 270 
DNAJC7 transcript levels (Supplementary Fig. 10A and B). These data indicate that DNAJC7 271 
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mRNA abundance is not significantly altered in fibroblasts harboring a DNAJC7 protein-272 
truncating variant (Fig. 5A). We next carried out immunoblot assays on protein lysates from 273 
fibroblasts and determined that DNAJC7 protein levels were significantly reduced in the ALS 274 
patient fibroblasts (Fig. 5B). Although this protein-truncating variant could potentially yield a 275 
17.5 kDa protein, no evidence for such a product was detected (Supplementary Fig. 10C). 276 
Together, our findings indicate the protein-truncating variants we identified in DNAJC7 leads to 277 
decreased protein levels of this heat shock protein co-chaperone. 278 
 279 
DISCUSSION 280 
Herein, we have assembled the exomes of 3,864 ALS cases and 7,839 controls and observed an 281 
exome-wide enrichment of protein-truncating variants, which typically result in protein loss-of-282 
function. The abundance of protein-truncating variants in ALS cases seems to be primarily 283 
driven by constrained genes, which are under strong purifying selection. When removing 284 
constrained genes, the initial exome-wide enrichment of protein-truncating variants remains; 285 
however, the effect sizes are much smaller, suggesting that while constraint genes may explain 286 
much of protein-truncating variant enrichment, there may be minor residual effects elsewhere in 287 
the genome. Accordingly, we examined the effects of ALS associated genes and did not observe 288 
any significant enrichment. Importantly, a subset of cases was pre-screened for known 289 
pathogenic variants in a select number of known ALS genes and positive cases were eliminated 290 
prior to assembling the dataset, which attenuated the effect size estimates and significance for 291 
genes in this gene set. 292 
Acknowledging the phenotypic variability of ALS, we also evaluated the effects of genes 293 
implicated in other motor neuron diseases such as primary lateral sclerosis, progressive muscular 294 
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atrophy, progressive bulbar palsy, and spinal muscular atrophy; as well as genes associated with 295 
IURQWRWHPSRUDOGHPHQWLD3DUNLQVRQ¶VGLVHDVH3LFN¶VGLVHDVHDQG$O]KHLPHU¶VGLVHDVH:HGLG296 
not observe a significant enrichment in any class of variation, suggesting that the initial 297 
observation of excess protein-truncating variants do not reside in these genes. Lastly, the genes 298 
implicated in the development of ALS are not specifically expressed in motor neurons, nor are 299 
they brain specific, despite the specific degree of degeneration of upper and lower motor 300 
neurons. Nevertheless, we tested whether the signal in protein-truncating variants is concentrated 301 
in brain specific genes, a much larger gene set than ALS genes only. We did not observe any 302 
significant enrichment within brain specific genes. 303 
The single gene burden analysis identified the most significant genes as SOD1, NEK1, 304 
and FUS, which are known ALS genes. No other individual gene passed exome-wide 305 
significance within our dataset (3,864 cases and 7,839 controls) and the additional controls in the 306 
secondary analysis (3,864 cases and 28,910 controls). Notably, in the secondary analysis, 307 
multiple genes with consistent OR and lower P-values than the initial analysis, surfaced. Within 308 
protein-truncating variants, these include: GRIN3B, HRCT1, IL3, and DNAJC7. Interestingly, 309 
protein-truncating variants in GRIN3B and HRCT1 may offer protection against ALS: OR: 0.05, 310 
P: 7.7×10-5; OR: 0.05, P: 1.2×10-4, respectively; while protein-truncating variants in IL3 and 311 
DNAJC7 may confer risk: OR: 10.5, P: 1.8×10-4; OR: 67.4, P: 1.9×10-4). 312 
In this analysis, DNAJC7 had 4 protein-truncating variant carriers in 3,864 cases and 0 in 313 
7,839 and 28,910 controls additionally, when integrating data from the UK Motor Neurone 314 
Disease Association, we observed an additional 4 protein-truncating variant carriers for a total of 315 
6 distinct protein-truncating variants in 8 individuals (initial analysis P: 0.01; secondary analysis 316 
P: 1.9×10-4; replication analysis P: 2.5×10-7). According to the HPA RNA-seq normal tissues 317 
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project21 and the Genotype-Tissue Expression (GTEx) project22, DNAJC7 is ubiquitously 318 
expressed with elevated expression in the brain. DNAJC7 encodes a molecular chaperone, DnaJ 319 
heat shock protein family (HSP40) member C7, and like all DNAJ proteins, contains an 320 
approximately 70 amino acid J-domain, which is critical for binding to HSP70 proteins23. There 321 
are approximately 50 DNAJ proteins, which are also classified as HSP40 proteins, that facilitate 322 
protein maintenance and quality control, such as folding of newly synthesized polypeptides, and 323 
clearance of degraded proteins15,24,25. Specifically, DNAJs act as co-chaperones for HSP70 324 
proteins by regulating ATPase activity, aid in polypeptide binding, and prevention of premature 325 
polypeptide folding25,26. 326 
Aberrant protein aggregation due to accumulation of misfolded proteins, is one of the 327 
pathological hallmarks of neurodegenerative GLVHDVHVOLNH$O]KHLPHU¶VGLVHDVH3DUNLQVRQ¶V328 
GLVHDVH+XQWLQJWRQ¶VGLVHDVHSULRQGLVHDVHDQG$/627-32. HSP proteins have a conserved and 329 
central role in protein function by aiding in their folding and stabilization, and the clearance of 330 
misfolded proteins, ultimately diminishing protein aggregates and the associated pathologies. 331 
However, genetic aberrations or cellular stress such as exposure to environmental toxins, 332 
fluctuations in temperature, chemical stress, cell injury, or aging, can influence the dynamics of 333 
the protein quality control network allowing misfolded proteins to go undetected thereby 334 
triggering neurotoxicity33,34. Furthermore, abnormal expression of HSP70 and DNAJ genes leads 335 
WRWKHIRUPDWLRQRISURWHLQDJJUHJDWHVLQPRGHOVRI$O]KHLPHU¶VGLVHDVH353DUNLQVRQ¶V336 
disease36,37+XQWLQJWRQ¶VGLVHDVH35,38, prion disease39,40, and ALS41-43. In light of these studies, 337 
elevated HSP expression is thought to be beneficial in preventing or in halting neurodegenerative 338 
disease progression44. For example, overexpression of DNAJB6b and DNAJB8 suppressed toxic 339 
protein aggregation45; while overexpression of HSP70 in neuroglioma cells decreased the 340 
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formation of alpha-synuclein fibrils46. Within ALS models, overexpression of HSPB8 promoted 341 
clearance of mutant SOD147; double transgenic mice overexpressing HSP27 and mutated SOD1 342 
exhibited increased survival of spinal motor neurons than mice overexpressing a SOD1 mutation 343 
only, however, the neuroprotective effects were not sustained in later stages of the disease48. 344 
Finally, DNAJB2, which when mutated can cause autosomal recessive spinal muscular atrophy, 345 
was overexpressed in mice motor neurons also expressing a SOD1 mutation (p.Gly93Ala), and 346 
led to reduced mutant SOD1 aggregation and improved motor neuron survival49. In 347 
Supplementary Table 4, we tabulated additional HSP genes that have been reported to harbor 348 
pathogenic or likely pathogenic mutations in patients with neurodegenerative diseases. 349 
In summary, we observed a significant exome-wide enrichment of protein-truncating 350 
variants, which seem to primarily reside in constrained genes. Through gene burden tests, we 351 
confirmed the known association of ALS genes SOD1, NEK1, and FUS, and also observed 352 
multiple protein-truncating variants in ALS cases in a highly constrained, HSP40 gene, DNAJC7. 353 
Our replication of protein-truncating variants in DNAJC7 in an independent ALS cohort as well 354 
as functional validation highlights loss of DNAJC7 as a novel genetic risk factor for ALS. 355 
 356 
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FIGURES 513 
 514 
Fig. 1. Exome wide enrichment of protein-truncating variants in ALS cases 515 
Exome wide analysis of synonymous variants, benign missense variants, damaging missense 516 
variants, and protein-truncating variants within singletons, doubletons, ultra-rare singletons, and 517 
rare variants. Odds ratios and 95% confidence intervals for each class of variation are depicted 518 
by different colors. P-values from firth logistic regression test are also displayed. Multiple test 519 
correction P-value: 0.0125. N=3,864 ALS cases; N=7,839 controls. The graph display the mean 520 
and standard deviation. 521 
 522 
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 523 
Fig. 2. Enrichment of protein-truncating variants in constrained genes in ALS cases 524 
a, Analysis of constrained genes only in synonymous variants, benign missense variants, 525 
damaging missense variants, and protein-truncating variants within ultra-rare singletons and rare 526 
variants. Odds ratios and 95% confidence intervals for each class of variation are depicted by 527 
different colors. P-values from firth logistic regression test are also displayed. Multiple test 528 
correction P-value: 0.0125. N=3,864 ALS cases; N=7,839 controls. The graphs display the mean 529 
and standard deviation. 530 
b, Exome-wide analysis with constrained genes removed. 531 
 532 
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 533 
Fig. 3. No enrichment of variants in known ALS genes, other related neurodegenerative 534 
disease genes, or brain specific genes 535 
a, Analysis of ALS genes. Synonymous variants, benign missense variants, damaging missense 536 
variants, and protein-truncating variants within singletons, doubletons, ultra-rare singletons, and 537 
rare variants are shown. Odds ratios and 95% confidence intervals for each class of variation are 538 
depicted by different colors. P-values from firth logistic regression test are also displayed. 539 
Multiple test correction P-value: 0.0125. N=3,864 ALS cases; N=7,839 controls. The graphs 540 
display the mean and standard deviation. 541 
  25 
b, Analysis of other neurodegenerative disease genes. 542 
c, Analysis of brain specific genes. 543 
 544 
 545 
Fig. 4. Quantile-quantile plot of discovery results for rare variants 546 
a, Rare protein-truncating variants in ALS dataset. X and Y axis represent the negative logarithm 547 
P-value. N=3,864 ALS cases; N=7,839 controls. The top 10 genes with their P-values are 548 
displayed. Genes in red and blue pass or approach exome-wide significance, respectively. The 549 
results displayed are from a EXUGHQDQDO\VLVXVLQJ)LVKHU¶VH[DFWWHVWDVZHOODV6.$7ZLWK550 
previously defined covariates (sample sex, PC1-PC10, and total exome count). Exome-wide 551 
correction for multiple testing was set at (P<2.5×10-6), which was the 5% type-I error rate 552 
multiplied by the number of genes tested. 553 
b, Rare damaging missense variants in ALS dataset. 554 
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c, Rare protein-truncating variants in ALS cases with an additional 21,071 non-Finnish European 555 
controls for a total of 28,910 controls. Genes in blue were the most significant genes in the 556 
discovery analysis. Genes in green were the most significant genes in the secondary analysis. 557 
d, Rare damaging missense variants in ALS cases and 28,910 controls. The top 10 genes with 558 
their P-values are displayed. 559 
 560 
 561 
Fig. 5. Effects of DNAJC7 protein-truncating variant p.Arg156Ter on transcript and 562 
protein levels.  563 
  27 
a, qRT-PCR analysis of DNAJC7 transcripts in human fibroblasts from healthy controls or a 564 
patient harboring a DNAJC7 protein-truncating variant p.Arg156Ter. Data were normalized to 565 
GAPDH and displayed as mean of 3 technical replicates with s.d. from two independent 566 
experiments with n=12 control and 1 patient lines (unpaired t test, two-sided, P<0.05). P-value is 567 
displayed, 0.1312. 568 
b, Immunoblot analysis for DNAJC7 protein levels in human fibroblast lysates. Protein levels 569 
were normalized to GAPDH and displayed relative to the average levels in healthy controls. Data 570 
are displayed as mean with s.d. of n=3 technical replicates (unpaired t test, two-sided, P< 0.05). 571 
P-value is displayed, <0.0001. The blot image was cropped to make this figure, for the full scan 572 
of the blot, please see Supplementary Fig. 10. 573 
 574 
TABLES 575 
Table 1. Top hits in protein-truncating variants model in initial (3,864 cases and 7,839 576 
controls), and secondary datasets (3,864 cases and 28,910 controls). 577 
 578 
Gene Initial OR Initial P-value Secondary OR Secondary P-value 
Protein truncating variants model 
NEK1 12.8 (25, 4) 4.6×10-9* 6.5 (25, 29) 3.0×10-10# 
DAK 42.7 (10, 0) 1.5×10-5 5.8 (10, 13) 1.4×10-4 
IRAK3 11.2 (11, 0) 2.0×10-4 2.1 (11, 40) 0.05 
OPTN 6.6 (13, 4) 3.0×10-4 2.6 (13, 38) 6.9×10-3 
SEC14L3 18.3 (9, 1) 3.0×10-4 1.4 (9, 48) 0.31 
VWA3B 5.7 (14, 5) 3.0×10-4 3.0 (14, 50) 0.02 
CDHR3 9.1 (9, 2) 1.3×10-3 1.4 (9, 70) 0.9 
ABCC2 3.1 (20, 13) 1.3×10-3 1.8 (20, 84) 0.03 
LRRC6 26.4 (6, 0) 1.3×10-3 1.2 (6, 38) 0.64 
FUS 26.4 (6, 0) 1.3×10-3 97.4 (6, 0) 2.7×10-6# 
GRIN3B 0.4 (0, 10) 0.04 0.05 (0, 80) 7.7×10-5# 
HRCT1 0.2 (0, 15) 4.1×10-3 0.05 (0, 78) 1.2×10-4# 
IL3 14.2 (7, 1) 2.4×10-3 10.5 (7, 5) 1.8×10-4# 
DNAJC7 18.3 (4, 0) 0.01 67.4 (4, 0) 1.9×10-4# 
KRT74 3.0 (9, 6) 0.05 8.7 (9, 11) 2.2×10-4# 
SLC26A10 0.1 (0, 9) 0.03 0.1 (0, 70) 2.7×10-4# 
FAM206A 4.1 (6, 3) 0.07 11.2 (6, 4) 3.7×10-4# 
TBK1 22.3 (5, 0) 3.9×10-3 12.5 (5, 3) 9.3×10-4# 
KLHDC4 0.1 (0, 14) 7.4 ×10-3 0.1 (0, 61) 9.8×10-4# 
DUOXA2 2.4 (7, 6) 0.14 5.8 (7, 9) 1.4×10-3# 
  28 
Damaging missense variants model 
SOD1 87.7 (21, 0) 7.5×10-11* 79.0 (21, 2) 6.0×10-18# 
ATRN 5.8 (20, 7) 1.4×10-5 2.0 (20, 74) 9.2×10-3 
HRASLS5 24.4 (12, 1) 1.5×10-5 1.6 (12, 56) 0.13 
TMEM79 5.8 (17, 6) 7.0×10-5 1.8 (17, 70) 0.03 
SYNE3 12.2 (12, 2) 7.3×10-5 1.1 (12, 79) 0.62 
LCP1 18.3 (9, 1) 3.3×10-4 3.7 (9, 18) 2.8×10-3 
SCAND3 5.7 (14, 5) 3.3×10-4 1.8 (14, 58) 0.06 
C6orf89 0.05 (0, 20) 4.7×10-4 0.05 (0, 47) 5.2×10-3 
EGF 6.1 (12, 4) 7.1×10-4 3.1 (12, 29) 2.1×10-3 
ZNF679 16.3 (8, 1) 8.9×10-4 4.6 (8, 13) 1.8×10-3 
THUMPD3 0.07 (0, 15) 4.1×10-3 0.08 (0, 76) 1.2×10-4# 
MEPCE 9.1 (9, 2) 1.3×10-3 6.7 (9, 10) 1.3×10-4# 
REG3G 5.4 (8, 3) 8.2×10-3 7.5 (8, 8) 2.0×10-4# 
USHBP1 0.09 (1, 22) 1.6×10-3 0.08 (1, 92) 2.6×10-4# 
WSCD2 3.6 (14, 8) 4.8×10-3 3.6 (14, 29) 2.7×10-4# 
WWTR1 26.4 (6, 0) 1.3×10-3 11.2 (6, 4) 3.7×10-4# 
FAM63B 0.08 (0, 12) 0.01 0.06 (0, 62) 6.2x10-4# 
*Passed exome-wide significance (P-value <2.5×10-6) in first analysis (3,864 cases and 7,839 579 
controls.#OR direction is maintained in secondary analysis (3,864 cases and 28,910 controls) and 580 
P-value is lower. Bolded genes have been previously reported in ALS. The results displayed are 581 
from a EXUGHQDQDO\VLVXVLQJ)LVKHU¶VH[DFWWHVWDVZHOODV6.$7ZLWKSUHYLRXVO\GHILQHG582 
covariates (sample sex, PC1-PC10, and total exome count). Exome-wide correction for multiple 583 
testing was set at (P<2.5×10-6), which was the 5% type-I error rate multiplied by the number of 584 
genes tested. 585 
 586 
 587 
Table 2. Protein-truncating variants DQGµGDPDJLQJ¶PLVVHQVHYDULDQWVLQDNAJC7. 588 
 589 
Variant 
type 
Variant location cDNA 
change 
Protein 
change 
Cases 
(n=5,095) 
Controls 
(n=28,910) 
gnomAD 
(non-neuro) 
AF 
CADD MPC 
Stop gain 17:g.40152569C>A c.97G>T p.E33X 1 0 0 39  
Stop gain 17:g.40148376G>A c.358C>T p.Q120X 1 0 0 37  
Stop gain 17:g.40146902G>A c.466C>T p.R156X 2 0 0 41  
Frameshift 17:g. 40142393delA c.488delT p. F163fs 1 0 0   
Stop gain 17:g.40141529G>A c.646C>T p.R216X 2 0 0 40  
Essential 
splice site 17:g. 40135656T>C c.1011-2A>G  1 0 0 26.3  
Missense 17:g.40169413C>G c.22G>C p.D8H 1 0 1.985×10-5 25 0.78 
Missense 17:g.40149189G>A c.235C>T p.R79W 0 1 1.204×10-5 35 1.58 
Missense 17:g. 40141544C>T c. 631G>A p. D211N 1 0 0 26.4 0.94 
Missense 17:g.40134023G>A c.1234C>T p.R412W 1 0 4.029×10-6 34 1.66 
Missense 17:g.40133984C>T c.1273G>A p.E425K 2 0 0 35 1.69 
AF, allele frequency; empty cell denotes inapplicable information. 590 
 591 
 592 
METHODS 593 
  29 
Study overview 594 
The familial ALS (FALS) and the ALS Genetics (ALSGENS) consortia were assembled to 595 
aggregate the existing ALS sequencing data in the community to improve the power to discover 596 
novel genetic risk factors for ALS. Herein, we describe our approach of assembling the largest 597 
ALS exome case-control study to date. 598 
 599 
Sample acquisition 600 
Blood samples were collected from subjects following appropriate and informed consent in 601 
accordance with the Research Ethics Board at each respective recruiting site within the CReATe, 602 
FALS, and ALSGENS consortia. All samples known to be carriers of the C9orf72 603 
hexanucleotide expansion (G4C2) were excluded from the study. Additionally, prior to exome 604 
sequencing, a subset of the samples (approximately 2,000) were genotyped and screened for 605 
known variants in known ALS genes, SOD1, FUS, and TARDBP; and were only included in our 606 
study if they were found to be negative for the variants tested. 607 
Exome sequencing data for control and a subset of case samples were downloaded from 608 
dbGAP and were not enriched for (but not specifically screened for) ALS or other 609 
neurodegenerative disorders. Control samples were matched to case samples with respect to 610 
similar capture kits and coverage levels. The age of control samples was not provided for all 611 
samples but in general, controls were older than typical age of onset of ALS. The data are 612 
available under the following accession codes: MIGen Exome Sequencing: Ottawa Heart 613 
(phs000806.v1.p1); MIGen Exome Sequencing: Leicester UK Heart Study (phs001000.v1.p1); 614 
Swedish Schizophrenia Population-Based Case-control Exome Sequencing (phs000473.v2.p2); 615 
Genome-Wide Association Study of Amyotrophic Lateral Sclerosis (phs000101.v5.p1). 616 
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No statistical methods were used to pre-determine sample sizes but our sample sizes are 617 
similar to those reported in previous publications9. Randomization of experimental groups was 618 
not applicable to this study. The experimental conditions are determined by each individual's 619 
genetics, which are fixed at conception. This reflects a randomization of the alleles inherited 620 
from each individual's parents (i.e.mendelian randomization), but it does not involve 621 
randomization of experimental parameters. Blinding was not relevant to the study as this study 622 
was composed of cases and controls. Therefore, the analyst needed to know the case-control 623 
status of every participant. 624 
 625 
Whole exome sequencing 626 
15,722 DNA samples were sequenced at the Broad Institute, Guy's Hospital, McGill University, 627 
Stanford University, HudsonAlpha, and University of Massachusetts, Worcester. Samples were 628 
sequenced using the exome Agilent All Exon (37MB, 50MB, or 65MB), Nimblegen SeqCap EZ 629 
V2.0 or 3.0 Exome Enrichment kit, Illumina GAIIx, HiSeq 2000, or HiSeq 2500 sequencers 630 
according to standard protocols. 631 
All samples were joint called together and were aligned to the consensus human genome 632 
sequence build GRCh37/hg19; and BAM files were processed using BWA Picard. Genotype 633 
FDOOLQJZDVSHUIRUPHGXVLQJWKH*HQRPH$QDO\VLV7RRONLW¶V*$7.+DSORW\SH&DOOHUDQGZDV634 
performed at the Broad Institute as previously described50,51. 635 
 636 
Hail software and quality control 637 
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Code availability: we used Hail, an open-source, scalable framework for exploring and analyzing 638 
genomic data https://hail.is/ to process the data. All quality control steps were performed using 639 
Hail 0.1 (Supplementary Table 1). 640 
 641 
(1) Sample QC and Variant QC 642 
Samples with high proportion of chimeric reads (>5%) and high contamination (>5%) were 643 
excluded. Samples with poor call rates (<90%), mean depth <10x, or mean genotype-quality <65 644 
were also eliminated from further analysis. 645 
For variant QC, we restricted to GENCODE coding regions, independent of capture 646 
interval, where both Agilent and Illumina exomes surpass 10x mean coverage. We restricted to 647 
µ3$66¶YDULDQWVLQ*$7.¶V9DULDQW4XDOLW\6FRUH5HFDOLEUDWLRQ9465ILOWHU,QGLYLGXDO648 
genotypes were filtered (set to missing) if they did not meet the following criteria: 1) genotype 649 
depth (g.DP) 10 or greater 2) Allele balance >=0.2 in heterozygous sites  or <= 0.8 for 650 
homozygous reference and homozygous alternate variants 3) Genotype quality (GQ)> 20 . 651 
Finally, we selected variants with call rate >90% and Hardy-Weinberg equilibrium test P-value 652 
>1×10-6. For quality control analysis, see Supplementary Table 1 and Supplementary Fig. 1. 653 
 654 
(2) Sex imputation 655 
We used the X chromosome inbreeding coefficient to impute sample sex. Samples with an X 656 
chromosome inbreeding coefficient >0.8 were classified as males and samples with an X 657 
chromosome inbreeding coefficient <0.4 were classified as females. Samples within <0.8 and 658 
>0.4 were classified as having ambiguous sex status, and therefore were excluded from the 659 
dataset (Supplementary Table 1). 660 
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 661 
(3) Principal component analysis 662 
Principal component analysis (PCA) was performed using Hail. We used a subset of high 663 
confidence SNPs in the exome capture region to calculate the principal components. We used 664 
only ancestry-matched cases and controls as indicated by overlapping population structure. 665 
Furthermore, we used 1000 Genomes samples to determine the general ethnicity of the ALS 666 
dataset. The majority of the samples in the ALS dataset were reported to be of European descent 667 
and this was confirmed by PCA with 1000 Genomes samples (Supplementary Fig. 2, 668 
Supplementary Table 1). 669 
 670 
(4) Relatedness check 671 
We included only unrelated individuals (IBD proportion < 0.2) (Supplementary Table 1). 672 
 673 
(5) Variant annotation 674 
We annotated protein-coding variants into four classes: (1) synonymous; (2) benign missense; 675 
(3) damaging missense; and (4) protein-truncating variants (PTV). Using VEP annotations 676 
(Version 85)52, we classified synonymous variants as: "synonymous_variant", 677 
"stop_retained_variant", and "incomplete_terminal_codon_variant". Missense variants were 678 
classified as: "inframe_deletion", "inframe_insertion", "missense_variant", "stop_lost", 679 
"start_lost", and "protein_altering_variant". Furthermore, benign missense variants were 680 
SUHGLFWHGDV³WROHUDWHG´DQG³EHQLJQ´E\3RO\3KHQ-2 and SIFT, respectively; whereas damaging 681 
PLVVHQVHYDULDQWVZHUHSUHGLFWHGDV³SUREDEO\GDPDJLQJ´DQG³GHOHWHULRXV´)inally, protein-682 
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truncating variants were classified as: "frameshift_variant", "splice_acceptor_variant", 683 
"splice_donor_variant", and "stop_gained". 684 
 685 
(6) Allele frequency categorization 686 
Allele frequencies were estimated within our case-control sample, and from two external exome 687 
sequence databases, DiscovEHR and ExAC53. DiscovEHR is a publicly available database with 688 
>50,000 exomes of participants who may have some health conditions however, they do not have 689 
ALS. ExAC is a mixture of healthy controls and complex disease patients, and we restricted to 690 
the non-psychiatric subset of ExAC for allele frequency estimation. Of note, many of our 691 
controls are present in the ExAC database, so we restricted to the DiscovEHR cohort to 692 
determine ultra-rare singletons. We did not use gnomAD for this analysis as our cases and our 693 
controls have been deposited into this resource. 694 
We classified variant allele frequency using the following criteria: (1) singletons, which 695 
are variants present in a single individual in our dataset (allele count, AC =1); (2) doubletons, 696 
which are present in two individuals in our dataset (AC = 2); (3) ultra-rare singletons, which are 697 
singletons in our dataset and are absent in DiscovEHR (AC = 1, 0 in DiscovEHR); and finally, 698 
(4) rare variants, which have a MAF of <0.01% in our dataset (11,703 samples), in ExAC (non-699 
psychiatric studies, >45,000 samples) and in DiscovEHR (>50,000 samples). 700 
 701 
Multivariate models used for analysis 702 
To determine whether an enrichment of a specific class of variation was present in ALS cases 703 
versus controls, we ran multiple Firth logistic regression models. The Firth penalization is used 704 
in the likelihood model due to the low counts in many tests, and helps to minimize the type I 705 
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error rate when multiple covariates are included in the model54. Model 1 predicted ALS case-706 
control status solely from variant count; Model 2 incorporated multiple covariates: (1) sample 707 
sex, (2) sample population structure from the first 10 principal components; Model 3 708 
incorporated all covariates used the second model along with (3) sample total exome count, 709 
which is the exome-wide count of variants in the specific frequency class tested. Finally, Model 710 
LVVLPLODUWR0RGHOEXWLQVWHDGXVHVWKH³EHQLJQYDULDQW´FRXQWDVDFRYDULDWHZKLFKLVWKH711 
exome-wide count of synonymous variants and benign missense variants only, rather than total 712 
exome count. Model 3, which we considered to be the most conservative model to represent the 713 
dataset, was used as the preferred model for our analysis (Supplementary Fig. 3). 714 
 715 
Exome-wide burden 716 
The four Firth logistic regression models above were used to predict case-control status from 717 
exome-wide counts of synonymous, missense, and protein-truncating variants. Given that 718 
sequencing errors are more prevalent when calling insertions or deletions (indels)55,56, we 719 
divided variants within the protein-truncating variants category as either 1) SNV-based protein-720 
truncating variants or 2) indel-based protein-truncating variants, due to single nucleotide variants 721 
(SNVs) or indels, respectively. This ensures that any enrichment observed in protein-truncating 722 
variants is not solely from indel-based protein-truncating variants. 723 
 724 
Gene sets 725 
(1) Constrained genes (pLI genes: 3,488, constrained missense genes: 1,730) 726 
We evaluated whether variation in loss of function intolerant (pLI) genes are associated with 727 
ALS using the same approach as described in the exome-wide approach however, we extracted 728 
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only high pLI genes from the exome. We obtained the genic pLI intolerance metrics from Lek et 729 
al., 2016 available online: 730 
(ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3/functional_gene_constraint/). For 731 
protein-truncating variants, we used genes with a probability of loss-of-function intolerant (pLI) 732 
>0.9. We also evaluated missense constrained genes generated by Samocha et al., 201457. For 733 
missense variants, we used genes with a z-score of >3.09. 734 
 735 
(2) ALS associated genes (38 genes) 736 
We also examined exome-wide burden with known ALS genes removed. The list of ALS genes 737 
are as follows: TARDBP, DCTN1, ALS2, CHMP2B, ARHGEF28, MATR3, SQSTM1, FIG4, 738 
HNRNPA2B1, C9orf72, SIGMAR1, VCP, SETX, OPTN, PRPH, HNRNPA1, DAO, ATXN2, ANG, 739 
FUS, PFN1, CENPV, TAF15, GRN, MAPT, PNPLA6, UNC13A, VAPB, SOD1, NEFH, ARPP21, 740 
and UBQLN2. We did not remove TBK1, NEK1, KIF5A, C21orf2, MOBP, or SCFD1 as these 741 
genes were discovered using datasets that contained a large subset of the same samples. We also 742 
performed an analysis with all proposed ALS genes. 743 
 744 
(3) Neurodegenerative disease genes (120 genes) 745 
We investigated whether genes associated with other neurodegenerative phenotypes showed 746 
enrichment in ALS cases. We included the following motor neuron diseases: primary lateral 747 
sclerosis, progressive muscular atrophy, progressive bulbar palsy, and spinal muscular atrophy. 748 
We also used genes associateGZLWK3DUNLQVRQ¶VGLVHDVHIURQWRWHPSRUDOGHPHQWLD3LFN¶V749 
GLVHDVHDQG$O]KHLPHU¶VGLVHDVHDVSDWLHQWVZLWK$/6FDQDOVRSUHVHQWZLWKIURQWRWHPSRUDO750 
dementia, cognitive impairment, or Parkinsonism (Supplementary Table 5). 751 
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 752 
(4) Brain expressed genes (2,650 genes) 753 
We evaluated whether genes expressed specifically in the brain were enriched for variation in 754 
our dataset. For this analysis, we used brain specific genes generated by Ganna et al., 2016. 755 
 756 
Single gene burden analysis 757 
(1) ALS dataset (3,864 cases and 7,839 controls) 758 
To determine whether a single gene is enriched or depleted for rare protein-coding variation in 759 
$/6FDVHVZHSHUIRUPHGDEXUGHQDQDO\VLVXVLQJ)LVKHU¶VH[DFWWHVWDVZHOODV6.$7ZLWK760 
previously defined covariates (sample sex, PC1-PC10, and total exome count). Exome-wide 761 
correction for multiple testing was set at (P<2.5×10-6), which was the 5% type-I error rate 762 
multiplied by the number of genes tested. We performed four different tests in ALS cases and 763 
controls: (1) ultra-rare protein-truncating variants (AC=1 and absent in DiscovEHR); (2) ultra-764 
rare damaging missense variants (AC=1 and absent in DiscovEHR); (3) rare protein-truncating 765 
variants (MAF <0.001% in the dataset, DiscovEHR, and ExAC); and (4) rare damaging missense 766 
variants (MAF <0.001% in the dataset, DiscovEHR, and ExAC). 767 
 768 
(2) ALS dataset and additional controls (3,864 cases and 28,910 controls) 769 
We also included an additional 21,071 samples from ExAC that are of European descent (non-770 
Finnish) and were not a part of any psychiatric or brain related studies, to eliminate any sample 771 
overlap. Furthermore, to mitigate against false discoveries, in addition to passing our QC filters, 772 
we ensured each variant also passed gnomAD (123,136 exomes and 15,496 genomes) QC filters. 773 
We included variants that were either a singleton (AC=1) in gnomAD or completely absent to 774 
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ensure we minimize the inclusion of an excess of variants that passed gnomAD QC, that were 775 
rare (MAF <0.001%), yet were still observed in a very high number of individuals and were 776 
likely, false positive variants. The additional 21,071 samples allowed us to perform a secondary 777 
analysis of the genes that approached statistical significance (P<2.5×10-6) and determine 778 
whether their OR and P-values are maintained and exceed statistical significance, respectively. 779 
Additionally, we also used the 21,071 controls to increase statistical power to detect any gene 780 
discoveries not detected in the original dataset. Importantly, we did not perform a joint PCA on 781 
the 21,071 non-Finnish European controls and our dataset, therefore, we are unable to 782 
completely match the ancestry of our dataset. 783 
 784 
Cell acquisition culture and authentication 785 
The fibroblasts used in this study were previously approved by the institutional review boards 786 
(IRBs) of Harvard University, Massachusetts General Hospital, and Columbia University. 787 
Specific point mutations were confirmed by PCR amplification followed by Sanger sequencing. 788 
Weekly, cultures were checked for mycoplasma contamination using the MycoAlert kit (Lonza) 789 
with no cell lines used in this study testing positive. The use of these cells at Harvard was further 790 
approved and determined not to constitute Human Subjects Research by the Committee on the 791 
Use of Human Subjects in Research at Harvard University. Human fibroblasts were grown with 792 
DMEM (Invitrogen) supplemented with 15% fetal bovine serum (VWR), 10 mM MEM Non-793 
essential amino acid (Millipore), and B-PHUFDSWRHWKDQROȝ0,QYLWURJHQDQGFXOWXUHGRQ794 
tissue culture dishes maintained in 5% CO2 incubators at 37ºC. Fibroblasts were passaged after 795 
reaching confluency using trypsin (Invitrogen). 796 
 797 
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Immunoblot assays 798 
For analysis of DNAJC7 protein expression levels, fibroblasts were lysed in RIPA buffer 799 
(150mM Sodium Chloride; 1% Triton X-100; 0.5% sodium deoxycholate; 0.1% SDS; 50 mM 800 
Tris pH 8.0) containing protease and phosphatase inhibitors (Roche) for 20 min on ice, and 801 
FHQWULIXJHGDWKLJKVSHHGWRUHPRYHLQVROXEOHFRPSRQHQWVȝ/RI5,3$EXIIHUSHUZHOORID802 
6-well plate were routinely used, which yielded aȝJRIWRWDOSURWHLQDVGHWHUPLQHGE\%&$803 
7KHUPR6FLHQWLILF)RULPPXQREORWDVVD\VȝJRIWRWDOSURWHLQZDVVHSDUDWHGE\6'6-PAGE 804 
(BioRad), transferred to PDVF membranes (BioRad) and probed with antibodies against 805 
DNAJC7 (1:1000, Abcam, Clone EPR13349) and GAPDH (1:1000, Millipore, Clone 6C5). LI-806 
COR software (Image Studios) was used to quantitate protein band signal, and GAPDH levels 807 
were used to normalized each sample. Data are from three technical replicates with n=12 control 808 
and 1 patient lines. To analyze the results from this experiment, we used an unpaired t test, two-809 
sided with a statistical threshold of P<0.05. 810 
 811 
RNA preparation and qRT-PCR 812 
Total RNA was isolated from fibroblasts using Trizol (InvitrogHQDFFRUGLQJWRPDQXIDFWXUHU¶V813 
instructionVȝ/RI7UL]ROZHUHDGGHGSHUZHOORIWKH-well cultures. A total of 300-1000ng 814 
of total RNA was then used to synthesize cDNA by reverse transcription according to the 815 
iSCRIPT kit (Bio-rad). Quantitative RT-PCR (qRT-PCR) was then performed using SYBR green 816 
(Bio-Rad) and the iCycler system (Bio-rad). Quantitative levels for all genes assayed were 817 
normalized using GAPDH expression. For comparison between control and patient lines, 818 
normalized expression was displayed relative to the average of pooled data points from the 819 
healthy controls. The primer sequences (forward, reverse) are for GAPDH 820 
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(AATGGTGAAGGTCGGTGTG, GTGGAGTCATACTGGAACATGTAG), DNAJC7 Exons 4-821 
6 (CAGTGAGGTTGGATGACAGTT, ACTCTTGTTGTGCCTGAGC), DNAJC7 Exons 13-14 822 
(TACTATCCTCTCTGATCCCAAGA, CCTTGTTCTCCAGCTGAGAG). Data are from three 823 
technical replicates with n=12 control and 1 patient lines. To analyze the results from this 824 
experiment, we used an unpaired t test, two-sided with a statistical threshold of P<0.05. 825 
 826 
Data presentation and statistical analysis 827 
In the figure elements, points and lines represent the median and standard deviation, respectively. 828 
The plots display the minimum to maximum. Data distribution was assumed to be normal but 829 
this was not formally tested. For the exome-wide and gene specific test, we build four models 830 
WKDWXVHILUWKORJLVWLFUHJUHVVLRQSOHDVHUHIHUWRµMultivariate models used for analysis¶LQWKH831 
Materials and Methods section. Multiple test correction P-value < 0.0125 was considered 832 
significant. For gene specific analyses, a multiple test correction P-value <2.5×10-6 was 833 
considered significant. For the immunoblot and qPCR assays, the statistical analyses were 834 
performed using a two-WDLOXQSDLUHG6WXGHQW¶VW-test, with a P value of *P<0.05 considered as 835 
significant using Prism 7 (Graph Pad). 836 
 837 
Reporting Summary  838 
Further information on research design is available in the Nature Research Life Sciences 839 
Reporting Summary linked to this article. 840 
 841 
Data availability 842 
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The sequencing data discussed in this publication were obtained through dbGaP and are 843 
available under the following accession codes: MIGen Exome Sequencing: Ottawa Heart 844 
(phs000806.v1.p1); MIGen Exome Sequencing: Leicester UK Heart Study (phs001000.v1.p1); 845 
Swedish Schizophrenia Population-Based Case-control Exome Sequencing (phs000473.v2.p2); 846 
Genome-Wide Association Study of Amyotrophic Lateral Sclerosis (phs000101.v5.p1). 847 
 848 
Code availability 849 
Code used to conduct the analysis is provided online. 850 
 851 
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Supplementary Fig. 1. Initial sample quality control analysis 
 
(A) Sample call rate. (B) Sample mean depth. (C) Sample mean genotype quality. (D) Sample transition 
to transversion ratio. (E) Sample heterozygous to homozygous ratio. (F) Sample insertion to deletion 
ratio. (G) Number of SNPs in each sample. (H) Number of singletons in each sample. N=3,864 ALS 
cases; N=7,839 controls. The box and whisker plots display the mean, minimum, and maximum. 
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Supplementary Fig. 2. Principal component analysis of ALS dataset with 1000 Genomes 
 
(A) PC1 and PC2 of ALS dataset with 1000 Genomes. Cases, controls, and the European population is 
shown. N=3,864 ALS cases; N=7,839 controls. Each point represents one individual. 
(B) PC1 and PC3 of ALS dataset with 1000 Genomes. Cases, controls, and the European population is 
shown. 
(C) PC2 and PC3 of ALS dataset with 1000 Genomes. Cases, controls, and the European population is 
shown. 
(D) PC1 and PC2 of ALS dataset with 1000 Genomes. Cases, controls, and the European subpopulations 
are shown. 
(E) PC1 and PC3 of ALS dataset with 1000 Genomes. Cases, controls, and the European subpopulations 
are shown. 
(F) PC2 and PC3 of ALS dataset with 1000 Genomes. Cases, controls, and the European subpopulations 
are shown. 
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Supplementary Fig. 3. All models together 
  
Model 1: Sample variation. The graph display the mean and standard deviation. P-values from firth 
logistic regression test are also displayed. Multiple test correction P-value: 0.0125. N=3,864 ALS cases; 
N=7,839 controls. 
Model 2: Sample variation, sample sex, PC1-PC10. 
Model 3: Sample variation, sample sex, PC1-PC10, and total exome count (summation of synonymous, 
benign missense, damaging missense, and PTV). 
Model 4: Sample variation, sample sex, PC1-PC10, and benign variation count (summation of 
synonymous and benign missense variation). 
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Supplementary Fig. 4. Exome wide enrichment of SNV-based PTVs and indel-based PTVs in ALS 
cases 
 
Extension of Fig. 1: Evaluating the effects of SNV-based and indel-based PTVs within singletons 
(AC=1), doubletons (AC=2), ultra-rare singletons (AC=1, 0 in DiscovEHR), and rare variants 
(MAF<0.01 in our dataset, DiscovEHR and ExAC). Odds ratios and 95% confidence intervals for each 
class of variation are depicted by different colors. P-values are also displayed. Model 3 evaluates sample 
variation with the covariates, sample sex, PC1-10, and total exome count (summation of synonymous 
variation, benign missense variation, damaging missense variation, and PTV SNV or PTV indel). Model 
4 evaluates sample variation with the covariates, sample sex, PC1-10, and benign variation (summation 
of synonymous and benign missense variation). The graph display the mean and standard deviation. P-
values from firth logistic regression test are also displayed. Multiple test correction P-value: 0.0125. 
N=3,864 ALS cases; N=7,839 controls. 
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Supplementary Fig. 5. Enrichment of variants in constrained genes in ALS cases 
  
Extension of Fig. 2A and 2B: (a) Evaluating the effects of constrained genes in synonymous variants, 
benign missense variants, damaging missense variants, and PTVs within singletons (AC=1), doubletons 
(AC=2), ultra-rare singletons (AC=1, 0 in DiscovEHR), and rare variants (MAF<0.01 in our dataset, 
DiscovEHR and ExAC). Odds ratios and 95% confidence intervals for each class of variation are 
depicted by different colors. P-values are also displayed. Model 3 evaluates sample variation with the 
covariates, sample sex, PC1-10, and total exome count (summation of synonymous variation, benign 
missense variation, damaging missense variation, and PTV). Model 4 evaluates sample variation with 
the covariates, sample sex, PC1-10, and benign variation (summation of synonymous and benign 
missense variation). (b) Evaluating the residual effects with constrained genes removed. The graph 
display the mean and standard deviation. P-values from firth logistic regression test are also displayed. 
Multiple test correction P-value: 0.0125. N=3,864 ALS cases; N=7,839 controls. 
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Supplementary Fig. 6. Burden analysis of known ALS genes 
  
Extension of Fig. 3A: Evaluating the effects of known ALS genes in synonymous variants, benign 
missense variants, damaging missense variants, and PTVs within singletons (AC=1), doubletons 
(AC=2), ultra-rare singletons (AC=1, 0 in DiscovEHR), and rare variants (MAF<0.01 in our dataset, 
DiscovEHR and ExAC). Odds ratios and 95% confidence intervals for each class of variation are 
depicted by different colors. P-values are also displayed. Model 3 evaluates sample variation with the 
covariates, sample sex, PC1-10, and total exome count (summation of synonymous variation, benign 
missense variation, damaging missense variation, and PTV). Model 4 evaluates sample variation with 
the covariates, sample sex, PC1-10, and benign variation (summation of synonymous and benign 
missense variation). The graph display the mean and standard deviation. P-values from firth logistic 
regression test are also displayed. Multiple test correction P-value: 0.0125. N=3,864 ALS cases; 
N=7,839 controls. 
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Supplementary Fig. 7. Analysis of other neurodegenerative disease genes 
  
Extension of Fig. 3B: Evaluating the effects of genes associated with other neurodegenerative disease 
(motor neuron diseases: primary lateral sclerosis, progressive muscular atrophy, progressive bulbar 
palsy, and spinal muscular atrophy; diseases with overlapping phenotypes: frontotemporal dementia, 
3DUNLQVRQ¶VGLVHDVH3LFN¶VGLVHDVHDQG$O]KHLPHU¶VGLVHDVHLQV\QRQ\PRXVYDULDQWVEHQLJQPLVVHQVH
variants, damaging missense variants, and PTVs within singletons (AC=1), doubletons (AC=2), ultra-
rare singletons (AC=1, 0 in DiscovEHR), and rare variants (MAF<0.01 in our dataset, DiscovEHR and 
ExAC). Odds ratios and 95% confidence intervals for each class of variation are depicted by different 
colors. P-values are also displayed. Model 3 evaluates sample variation with the covariates, sample sex, 
PC1-10, and total exome count (summation of synonymous variation, benign missense variation, 
damaging missense variation, and PTV). Model 4 evaluates sample variation with the covariates, sample 
sex, PC1-10, and benign variation (summation of synonymous and benign missense variation). The 
graph display the mean and standard deviation. P-values from firth logistic regression test are also 
displayed. Multiple test correction P-value: 0.0125. N=3,864 ALS cases; N=7,839 controls. 
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Supplementary Fig. 8. Analysis of brain specific genes 
  
Extension of Fig. 3C: Analysis of brain specific genes in synonymous variants, benign missense 
variants, damaging missense variants, and PTVs within singletons (AC=1), doubletons (AC=2), ultra-
rare singletons (AC=1, 0 in DiscovEHR), and rare variants (MAF<0.01 in our dataset, DiscovEHR and 
ExAC). Odds ratios and 95% confidence intervals for each class of variation are depicted by different 
colors. P-values are also displayed. Model 3 evaluates sample variation with the covariates, sample sex, 
PC1-10, and total exome count (summation of synonymous variation, benign missense variation, 
damaging missense variation, and PTV). Model 4 evaluates sample variation with the covariates, sample 
sex, PC1-10, and benign variation (summation of synonymous and benign missense variation). The 
graph display the mean and standard deviation. P-values from firth logistic regression test are also 
displayed. Multiple test correction P-value: 0.0125. N=3,864 ALS cases; N=7,839 controls. 
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Supplementary Fig. 9. Quantile-quantile plots of ultra-rare singletons. 
  
(a) Ultra-rare singletons (AC=1, 0 in DiscovEHR database) for PTV. PTVs in NEK1 and OPTN, which 
are known ALS genes, are enriched in ALS cases. NEK1 and OPTN P-values are displayed. (b) Ultra-
rare singleton (AC=1, 0 in DiscovEHR database) for damaging missense variants. Damaging missense 
variants in SOD1 are enriched in ALS cases. SOD1 P-value is displayed. 
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Supplementary Fig. 10. DNAJC7 qPCR and immunoblot assays 
 
(A-B) Relative levels of DNAJC7 mRNA in human fibroblasts using either primers recognizing 
exons 4 and 6 (A) or exons 13 and 14 (B). Levels for each sample were normalized to GAPDH and 
displayed relative to the average normalized levels of the healthy controls. Data are displayed as the 
mean of technical replicates with SD. (C) Uncropped immunoblot of human fibroblast protein lysates 
probed for the N-terminus of DNAJC7. Similar results were obtained in n=3 independent blots. 
